Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Migenix Amends Protocol in Hepatitis C Study
RxTrials Institute Drug Pipeline Alert
Feb. 6, 2008 | Vol. 6 No. 6
Migenix Amends Protocol in Hepatitis C Study
Migenix will add a 600-mg celgosivir combination therapy arm to its Phase II study in treatment-naive hepatitis C patients.
The 12-week, randomized, active-controlled study initially enrolled 20 patients in two treatment arms: peginterferon alfa-2b plus ribavirin and the combination plus 400-mg celgosivir.
The approved protocol amendment allows for the addition of the 600-mg arm and the flexibility to increase the number of patients in the study to a maximum of 50, Migenix said.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.